ArticleCureus2026
Ischemic Stroke During Rivaroxaban Therapy: The Importance of Food-Dependent Absorption and Careful Assessment Before Antithrombotic Escalation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke occurring during direct oral anticoagulant (DOAC) therapy for atrial fibrillation represents a frequent and challenging clinical dilemma due to increasing stroke rates and increasing DOAC prescription rates. Such events are often interpreted as treatment failure, prompting escalation with antiplatelet therapy, particularly in the presence of concomitant intracranial atherosclerotic disease (ICAD), and thereby exposing patients to increased bleeding risk. However, apparent DOAC failure may reflect correctable pharmacokinetic or adherence-related factors. We report a 75-year-old man with nonvalvular atrial fibrillation who presented with acute left-sided cerebellar ataxia and inability to sit unsupported. Neuroimaging demonstrated a posterior circulation ischemic stroke associated with intracranial atherosclerotic occlusion of the left vertebral artery, with collateral filling of the left posterior inferior cerebellar artery from the contralateral vertebral artery. Endovascular recanalization was unsuccessful, and the patient received short-term tirofiban due to the identified ICAD, with no hemorrhagic transformation on follow-up imaging. Although the stroke occurred during rivaroxaban therapy, detailed history revealed intake of rivaroxaban 20 mg once daily without food, likely resulting in reduced bioavailability. The event was interpreted as pharmacokinetic underexposure rather than true anticoagulant failure. Antiplatelet escalation was avoided, and anticoagulation was resumed with a food-independent DOAC. The patient remained clinically stable without hemorrhagic complications. This case highlights the importance of careful medication history and pharmacokinetic awareness in patients presenting with ischemic stroke during DOAC therapy. Recognizing apparent rather than true treatment failure can prevent unnecessary antithrombotic escalation and reduce avoidable bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.